Thrombocythemia, Essential research hub
6 indexed studies · 3 currently recruiting
- recruitingPHASE3
A Study to Evaluate Safety and Efficacy of Bomedemstat (MK-3543-017)
This study is for people already taking a medicine called bomedemstat for certain blood cancers like thrombocythemia or myelofibrosis. It aims to gather more information over a longer time about how safe and effective bomedemstat is for those who are already benefiting from it.
United States · Australia · Hong Kong - active not recruitingPHASE1, PHASE2
INCB000928 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Anemia Due to Myeloproliferative Disorders
This study looks at a new drug, INCB000928, by itself or with ruxolitinib, for people with myelofibrosis who have anaemia (low red blood cells) and need blood transfusions, or have anaemia symptoms. It aims to find a safe and effective dose.
United States · Canada · France - active not recruitingPHASE3
Phase 3 Study of Pelabresib (CPI-0610) in Myelofibrosis (MF) (MANIFEST-2)
This study is testing a new medicine called pelabresib alongside an existing treatment (ruxolitinib) for adults with myelofibrosis who haven't tried similar drugs before. It aims to see if this combination works better than ruxolitinib alone to help manage symptoms and spleen size.
United States · Australia · Austria - recruiting
Research Platform Myelofibrosis and Anemia
This study in Germany looks at how people with myelofibrosis and anaemia are treated in real life. It collects information about their health, treatments, and how they feel over time to understand common treatment patterns and changes in their care.
Germany - recruitingPHASE1
A Phase 1 Study of AJ1-11095 in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (PPV-MF), or Post-Essential Thrombocythemia Myelofibrosis (PET-MF) Who Have Been Failed by a Type I JAK2 Inhibitor (JAK2i)
This study is testing a new drug, AJ1-11095, for people with myelofibrosis whose current JAK2 inhibitor treatment is no longer working well. We want to see if it's safe and how it affects the condition.
United States · France · Italy - active not recruitingPHASE3
A Phase 3 Study of Pacritinib in Patients With Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis
This study looks at a new drug, pacritinib, for people with myelofibrosis and very low platelet counts. It compares pacritinib to other standard treatments decided by your doctor, to see if it can help improve symptoms.
United States · Australia · Belarus